Anti-TNFα therapy in the management of psoriasis: experience of a state referral center
BACKGROUND:Psoriasis is a chronic immune-mediated disease, characterized by increased levels of TNFα. Anti-TNFα agents have revolutionized the treatment of severe psoriasis by targeting an important molecule involved in its pathogenesis.OBJECTIVES:We report the experience of a state referral center...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Sociedade Brasileira de Dermatologia
2014-06-01
|
Series: | Anais Brasileiros de Dermatologia |
Subjects: | |
Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962014000300436&tlng=en |
_version_ | 1798020327348895744 |
---|---|
author | Laura Maria Andrade Silva Bruno de Oliveira Rocha Ana Cláudia Pinto Nobre Vitória Regina Pedreira de Almeida Rêgo Ivonise Follador Maria de Fátima Santos Paim de Oliveira |
author_facet | Laura Maria Andrade Silva Bruno de Oliveira Rocha Ana Cláudia Pinto Nobre Vitória Regina Pedreira de Almeida Rêgo Ivonise Follador Maria de Fátima Santos Paim de Oliveira |
author_sort | Laura Maria Andrade Silva |
collection | DOAJ |
description | BACKGROUND:Psoriasis is a chronic immune-mediated disease, characterized by increased levels of TNFα. Anti-TNFα agents have revolutionized the treatment of severe psoriasis by targeting an important molecule involved in its pathogenesis.OBJECTIVES:We report the experience of a state referral center that uses anti-TNFα agents for psoriasis.METHODS:We conducted a retrospective case series. Seventy-four out of 120 patients met the inclusion criteria. Clinical and laboratory data was analyzed using the chi-squared, Wicoxon and McNemar's tests. Associations were considered statistically significant when p-value<0.05.RESULTS:Forty-one subjects (55.40%) were male, with a mean age of 47.69±14.99 years. Median disease duration and pre-treatment PASI were 14.0 months (IQR 9.0-20.0), and 13.55 points (IQR 8.5-20.32). Sixty patients (81.10%) had arthropathic psoriasis. Forty-six subjects (62.20%) had comorbidities; the most frequent was dyslipidemia (25.70%). In 55.40% of patients, insufficient response to conventional therapies was the principal indication for using anti-TNFα drugs. Clinical improvement occurred in 93.20% of cases, and the post-treatment PASI median was 0.0 points (IQR 0.0-0.0). Adverse effects occurred in 6.80% of patients. Infections and elevation of transaminases occurred in 28.40% and 8.10% of cases, respectively.CONCLUSION:Post-treatment reduction in PASI was satisfactory and the occurrence of adverse effects was minor, mostly mild infusion effects and local reactions at drug administration sites. |
first_indexed | 2024-04-11T16:55:49Z |
format | Article |
id | doaj.art-b2233cf5239a42399d1d1ab8ef3ea8e0 |
institution | Directory Open Access Journal |
issn | 0365-0596 |
language | English |
last_indexed | 2024-04-11T16:55:49Z |
publishDate | 2014-06-01 |
publisher | Sociedade Brasileira de Dermatologia |
record_format | Article |
series | Anais Brasileiros de Dermatologia |
spelling | doaj.art-b2233cf5239a42399d1d1ab8ef3ea8e02022-12-22T04:13:16ZengSociedade Brasileira de DermatologiaAnais Brasileiros de Dermatologia0365-05962014-06-0189343644010.1590/abd1806-4841.20142613Anti-TNFα therapy in the management of psoriasis: experience of a state referral centerLaura Maria Andrade SilvaBruno de Oliveira RochaAna Cláudia Pinto NobreVitória Regina Pedreira de Almeida RêgoIvonise FolladorMaria de Fátima Santos Paim de OliveiraBACKGROUND:Psoriasis is a chronic immune-mediated disease, characterized by increased levels of TNFα. Anti-TNFα agents have revolutionized the treatment of severe psoriasis by targeting an important molecule involved in its pathogenesis.OBJECTIVES:We report the experience of a state referral center that uses anti-TNFα agents for psoriasis.METHODS:We conducted a retrospective case series. Seventy-four out of 120 patients met the inclusion criteria. Clinical and laboratory data was analyzed using the chi-squared, Wicoxon and McNemar's tests. Associations were considered statistically significant when p-value<0.05.RESULTS:Forty-one subjects (55.40%) were male, with a mean age of 47.69±14.99 years. Median disease duration and pre-treatment PASI were 14.0 months (IQR 9.0-20.0), and 13.55 points (IQR 8.5-20.32). Sixty patients (81.10%) had arthropathic psoriasis. Forty-six subjects (62.20%) had comorbidities; the most frequent was dyslipidemia (25.70%). In 55.40% of patients, insufficient response to conventional therapies was the principal indication for using anti-TNFα drugs. Clinical improvement occurred in 93.20% of cases, and the post-treatment PASI median was 0.0 points (IQR 0.0-0.0). Adverse effects occurred in 6.80% of patients. Infections and elevation of transaminases occurred in 28.40% and 8.10% of cases, respectively.CONCLUSION:Post-treatment reduction in PASI was satisfactory and the occurrence of adverse effects was minor, mostly mild infusion effects and local reactions at drug administration sites.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962014000300436&tlng=enPsoriatic arthritisPsoriasisTumor necrosis factor-alpha |
spellingShingle | Laura Maria Andrade Silva Bruno de Oliveira Rocha Ana Cláudia Pinto Nobre Vitória Regina Pedreira de Almeida Rêgo Ivonise Follador Maria de Fátima Santos Paim de Oliveira Anti-TNFα therapy in the management of psoriasis: experience of a state referral center Anais Brasileiros de Dermatologia Psoriatic arthritis Psoriasis Tumor necrosis factor-alpha |
title | Anti-TNFα therapy in the management of psoriasis: experience of a state referral center |
title_full | Anti-TNFα therapy in the management of psoriasis: experience of a state referral center |
title_fullStr | Anti-TNFα therapy in the management of psoriasis: experience of a state referral center |
title_full_unstemmed | Anti-TNFα therapy in the management of psoriasis: experience of a state referral center |
title_short | Anti-TNFα therapy in the management of psoriasis: experience of a state referral center |
title_sort | anti tnfα therapy in the management of psoriasis experience of a state referral center |
topic | Psoriatic arthritis Psoriasis Tumor necrosis factor-alpha |
url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962014000300436&tlng=en |
work_keys_str_mv | AT lauramariaandradesilva antitnfatherapyinthemanagementofpsoriasisexperienceofastatereferralcenter AT brunodeoliveirarocha antitnfatherapyinthemanagementofpsoriasisexperienceofastatereferralcenter AT anaclaudiapintonobre antitnfatherapyinthemanagementofpsoriasisexperienceofastatereferralcenter AT vitoriareginapedreiradealmeidarego antitnfatherapyinthemanagementofpsoriasisexperienceofastatereferralcenter AT ivonisefollador antitnfatherapyinthemanagementofpsoriasisexperienceofastatereferralcenter AT mariadefatimasantospaimdeoliveira antitnfatherapyinthemanagementofpsoriasisexperienceofastatereferralcenter |